| Literature DB >> 36230494 |
Abdelhakim Bouyahya1, Nasreddine El Omari2, Saad Bakrim3, Naoufal El Hachlafi4, Abdelaali Balahbib5, Polrat Wilairatana6, Mohammad S Mubarak7.
Abstract
Despite the significant advances and mechanistic understanding of tumor processes, therapeutic agents against different types of cancer still have a high rate of recurrence associated with the development of resistance by tumor cells. This chemoresistance involves several mechanisms, including the programming of glucose metabolism, mitochondrial damage, and lysosome dysfunction. However, combining several anticancer agents can decrease resistance and increase therapeutic efficacy. Furthermore, this treatment can improve the effectiveness of chemotherapy. This work focuses on the recent advances in using natural bioactive molecules derived from phenolic compounds isolated from medicinal plants to sensitize cancer cells towards chemotherapeutic agents and their application in combination with conventional anticancer drugs. Dietary phenolic compounds such as resveratrol, gallic acid, caffeic acid, rosmarinic acid, sinapic acid, and curcumin exhibit remarkable anticancer activities through sub-cellular, cellular, and molecular mechanisms. These compounds have recently revealed their capacity to increase the sensitivity of different human cancers to the used chemotherapeutic drugs. Moreover, they can increase the effectiveness and improve the therapeutic index of some used chemotherapeutic agents. The involved mechanisms are complex and stochastic, and involve different signaling pathways in cancer checkpoints, including reactive oxygen species signaling pathways in mitochondria, autophagy-related pathways, proteasome oncogene degradation, and epigenetic perturbations.Entities:
Keywords: cancer; chemotherapy; combination treatment; dietary phenolic compounds; drugs resistance; drugs sensibilization
Year: 2022 PMID: 36230494 PMCID: PMC9558505 DOI: 10.3390/cancers14194573
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1Mechanisms of chemoresistance of cancer cells against anticancer drugs.
Flavonoids improve the chemosensitivity of chemotherapeutic drugs in cancer.
| Molecules | Origins | Experimental Approaches | Key Results | References |
|---|---|---|---|---|
| Apigenin | Synthetized | MDA435/LCC6 and P388 cells | Enhanced the cytotoxicity of paclitaxel (PTX), doxorubicin (Dox), daunomycin (DM), vincristine (VCR), and vinblastine, resulting in a reduction of IC50 by 5–50 times | [ |
| Purchased | Parental human HCC cells (BEL-7402) and BEL-7402/ADM cells | Sensitized Dox-resistant BEL-7402 (BEL- 7402/ADM) cells to Dox | [ | |
| Purchased | Human pancreatic cancer cell line BxPC-3 Human pancreatic ductal epithelium (HPDE) cells | APG (13 μM) + gemcitabine (Gem) (13 μM) inhibited cell proliferation | [ | |
| Purchased | Human pancreatic cancer cell lines AsPc-1, Panc-1, and MiaPaCa-2 | Reduced cell growth | [ | |
| Purchased | Laryngeal carcinoma Hep-2 cell line | Enhanced the cisplatin (CP)-induced suppression of Hep-2 cell growth in a concentration- and time-dependent manner | [ | |
| Purchased | Laryngeal hep-2 carcinoma cell line | Improved xenograft radio-sensitivity | [ | |
| Purchased | Tumor xenografts in nude mice | Enhanced the cytotoxicity of 5-FU in HCC cells | [ | |
| Purchased | Human renal proximal tubular epithelial (HK-2) cells | Inhibited the CP-induced apoptosis of HK-2 cells | [ | |
| Purchased | 80 Swiss albino male mice | APG alone or combined with 5-FU | [ | |
| Not reported | BEL-7402 and BEL-7402/ADM cells | Reversed Dox sensitivity | [ | |
| Not reported | Human hepatocellular carcinoma (HCC) and adjacent normal tissue specimens | Enhanced Dox sensitivity | [ | |
| Purchased | Ovarian cancer-sensitive cell line SKOV3 | Enhanced the chemosensitivity of ovarian cancer-sensitive cells and drug-resistant cells | [ | |
| Quercetin | Purchased | DB-1 melanoma and SK Mel 28 cell lines Western blot analysis | Induced a redistribution of ΔNp73 in the cytoplasm and nucleus | [ |
| Not reported | Human esophageal cancer cells (EC9706 and Eca109) | Que + 5-FU inhibited growth and stimulated apoptosis in EC9706 and Eca109 esophageal cancer cells compared to Que | [ | |
| Purchased | MCF-7 and MCF-7/Dox cells | Increased intracellular concentration of Dox | [ | |
| Not reported | Human ovarian cancer cell lines, SKOV-3, EFO27, OVCAR-3, and A2780P | Inhibited proliferation and increased sensitivity of ovarian cancer cells to CP and PTX | [ | |
| Purchased | U251 and U87 human glioblastoma cells | Que (30 μmol/L) + TMZ (100 μmol/L) inhibited cell viability and enhanced TMZ inhibition | [ | |
| Purchased | MCF-7 cells and MCF-7/Dox cells | Que + Dox inhibited cell proliferation and invasion | [ | |
| Purchased | Lung cancer cells (A549 and H460 cells) | Reduced cell viability | [ | |
| Not reported | BEL-7402 and multidrug-resistant cell line BEL/5-FU | Increased intracellular accumulation of Dox | [ | |
| Purchased | Human prostate cancer cell line PC3 | Inhibited c-met expression and the downstream PI3K/AKT pathway | [ | |
| Purchased | Human pancreatic cancer cell lines | Attenuated RAGE expression to facilitate cell cycle arrest, autophagy, apoptosis, and GEM chemosensitivity in MIA Paca-2 GEMR cells | [ | |
| Purchased | Human prostate cancer (PC-3) cell lines | Que + PTX inhibited cell proliferation, increased apoptosis, arrested cell cycle at the G2/M phase, inhibited cell migration, induced ER stress, and increased ROS generation | [ | |
| Not reported | MCF 7 cells | Quer + 5-FU improved apoptosis by increasing the gene expression of Bax and p53 and caspase-9 activity and decreasing Bcl2 gene expression | [ | |
| Purchased | MDA-MB-231 human breast cancer cell line | Decreased cell viability | [ | |
| Kaempferol | Purchased | Human myelogenous leukemia K562 cells and the adriamycin-resistant variant K562/A cells | Kae + Que inhibited the growth of both cells | [ |
| Purchased | LS174 colon cancer cells | Chemo-sensitized 5-FU-resistant LS174-R cells | [ | |
| Purchased | Human colorectal cancer cell line HCT8 | Reversed the drug resistance of HCT8-R cells to 5-FU | [ | |
| Myricetin | Purchased | Esophageal carcinoma EC9706 cells | MYR + 5-FU suppressed cell survival fraction and proliferation, and increased cell apoptosis | [ |
| Purchased | A2780 and OVCAR3 ovarian cancer cells | Induced cytotoxicity, with an IC50 value of 25 μM | [ | |
| Rutin | Purchased | Human breast cancer MDA- MB-231 cellsCalcein acetoxymethyl accumulation assayRhodamine-123 uptake assay | Increased the anticancer activity of both chemotherapeutic agents | [ |
| Purchased | Human HCC cell lines | Attenuated autophagy and BANCR expression in SO-resistant cells | [ | |
| Hispidulin | Not reported | Human gallbladder carcinoma cell line GBC-SD | Inhibited the growth of GBC cells | [ |
Figure 2Chemical structures of flavonoids that improve the chemosensitivity of anticancer drugs.
Figure 3Mechanisms of chemosensitivity of apigenin towards sisplatin.
Anthocyanidins that could enhance the chemosensitivity of cancer drugs.
| Molecules | Origins | Experimental Approaches | Key Results | References |
|---|---|---|---|---|
| Delphinidin | Purchased | A549 cell line (human, lung, and carcinoma) | Induced apoptosis in A549 cells | [ |
| Cyanidin-3-glucoside (C3G) | Purchased | Human lung adenocarcinoma A549 cells | Reduced protein level of CLDN2 in A549 cells | [ |
| Anthocyanins (ACNs) | Black raspberry | Colon cancer cell lines, SW480 and Caco2MTT assay | Improved the chemotherapy efficacy of 5-FU and celecoxib | [ |
Figure 4Chemical structures of anthocyanidins that improve chemosensitivity of anticancer drugs.
Phenolic acids that improve the chemosensitivity of cancer drugs.
| Molecules | Origins | Experimental Approaches | Key Results | References |
|---|---|---|---|---|
| Caffeic acid phenethyl ester (CAPE) | Not reported | Mouse CT26 colorectal adenocarcinoma cells | Depleted intracellular GSH in CT26 cells, but not in bone marrow cells | [ |
| Purchased | Human medulloblastoma Daoy cell line and Human astroglia SVGp12 | Inhibited Daoy cell growth in a time- and concentration-dependent manner | [ | |
| Purchased | Parental and the drug-resistant cells of stomach (MKN45) and colon (LoVo) cancers | Potentiated the apoptotic effects of Dox and CP against parental cells | [ | |
| Not reported | Human lung adenocarcinoma A549 and RERF-LC-MS cell lines | Decreased claudin-2 protein level in a concentration-dependent manner | [ | |
| Not reported | Prostate cancer (PCa) cells, DU145 and PC3 Evaluated the radiomodulatory potential of CAPE | CAPE + gamma radiation (GR) sensitized PCa cells to radiation in a concentration-dependent manner | [ | |
| Ferulic acid (FA) | Purchased | Multidrug resistance (MDR) cell lines | Inhibited P-glycoprotein transport function in drug-resistant | [ |
| Purchased | Parental KB cells and P−gp overexpressing KB ChR8-5 cell lines | Increased the cytotoxicity of Dox and VCR in the P-gp overexpressing KB ChR8-5 cells | [ | |
| Rosmarinic acid (RA) | Purchased | Human acute promyelocytic leukemia NB4 cells | Potentiated ATRA-induced macrophage differentiation in APL cells | [ |
| Not reported | Human gastric carcinoma cell line SGC7901 | Increased the chemosensitivity of SGC7901 cells to 5-FUReduced IC50 of 5-FU (70.43 ± 1.06 μg/mL) compared to untreated SGC7901/5-FU cells (208.6 ± 1.09 μg/mL) | [ |
Figure 5Chemical structures of phenolic acids that improve the chemosensitivity of anticancer drugs.
Condensed tannins that could improve the chemosensitivity of cancer drugs.
| Molecules | Origins | Experimental Approaches | Key Results | References |
|---|---|---|---|---|
| Proanthocyanidins | Chinese bayberry leaves | Platinum-resistant human ovarian cancer cell line OVCAR-3 | Induced inhibitory effects on the growth and CSC characteristics of OVCAR−3 SP cells | [ |
| Grape seed extract | Colorectal cancer cell lines, HCT116 and H716 | Sensitized acquired (HCT116-FOr cells) and innately chemoresistant (H716 cells) cancer cells to 5-FU and oxaliplatin (OXP) | [ | |
| Tannic acid | Purchased | Malignant human cholangiocytes | Decreased malignant cholangiocyte growth | [ |
| Purchased | Liver cancer cell line HepG2 | Inhibited HepG2 cell growth | [ | |
| Procyanidins | Not reported | Laryngeal cancer cell line TU686 | Inhibited TU686 cells in a concentration-dependent manner for 24 h | [ |
| Ellagic acid | Purchased | Colorectal carcinoma HT−29, Colo 320DM, SW480, and LoVo cells | EA + 5-FU inhibited cell proliferation of HT-29, Colo 320DM and SW480 cells | [ |
| Purchased | Epithelial ovarian cancer cell line A2780MTT assay | Enhanced CP cytotoxicity in A2780CisR cells | [ | |
| Purchased | Caco-2 and HTC-116 cells | Induced higher cell viability than EA-NP treated HCT−116 cells | [ | |
| Purchased | Rat C6 glioma cells | Reduced MGMT expression | [ | |
| Purchased | Rat C6 glioma cells | EA + TMZ reduced cell viability | [ | |
| Purchased | Four human bladder cancer cell lines, TSGH−8301, TSGH-9202, T24, and J82 | Induced high cytotoxicity of Gem in GEM−resistant cells | [ |
Figure 6Chemical structures of tannins that improve chemosensitivity of anticancer drugs.